1 |
2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
|
2 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
|
3 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
4 |
Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
|
5 |
In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
|
6 |
The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29.
|
7 |
Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
|
8 |
A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
|
9 |
Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
|
10 |
Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
|
11 |
Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.
|
|
|
|
|
|
|